Kaplan Fox Encourages AEVEX Corp. (NYSE: AVEX) Investors to Contact the Firm Before the Lead Plaintiff Deadline on October 20, 2026

This is primarily a supply-overhang story, not a damages story. If the market starts to believe there was an embedded path to earlier monetization by the sponsor, the stock should trade with a higher dilution and governance discount because every future capital raise, follow-on, or insider sale becomes a credibility event. That matters most for a fresh IPO where the investor base is still forming; even a weak complaint can pressure the stock because marginal buyers do not want to underwrite a possible second wave of stock supply.

The key catalyst window is the next 1-2 months, not the eventual court timeline. The price reaction will be driven by whether any secondary registration, lock-up waiver, or amended disclosure appears into the lock-up expiration/lead-plaintiff period; that would confirm the market’s worst fear and likely extend underperformance. If nothing materializes and the company simply sits inside the normal discovery process, the headline risk fades faster than most litigation trades because the economic harm is contingent on actual share supply, not legal optics.

Contrarian view: the market may be overpricing lawsuit severity while underpricing the possibility that the real issue is just a reputational air pocket. If no secondary is filed, this can revert to a standard post-IPO volatility trade and the stock could rebound sharply on any clean filing or insider silence. For large underwriters, any read-through is more about process scrutiny and tougher future deal terms than near-term earnings risk unless their name becomes central in discovery.